Download PDF
CC BY-NC-ND 4.0 · AJP Rep 2017; 07(01): e39-e43
DOI: 10.1055/s-0037-1599133
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Management of Breast Cancer during Pregnancy: Are We Compliant with Current Guidelines?

Victoria Shlensky
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park Ridge, Illinois
,
Sigrun Hallmeyer
2   Division of Hematology and Oncology, Center for Advanced Care, Advocate Lutheran General Hospital, Park Ridge, Illinois
,
Lourdes Juarez
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park Ridge, Illinois
,
Barbara V. Parilla
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park Ridge, Illinois
› Author Affiliations
Further Information

Publication History

18 October 2016

03 January 2017

Publication Date:
28 February 2017 (online)

   Permissions and Reprints

Abstract

Introduction The purpose of this study was to evaluate the management of patients with breast cancer in pregnancy treated at the Advocate Health Care, to determine whether these patients were treated according to guidelines for pregnant patients, which aim to maximize both fetal and maternal outcomes.

Methods A retrospective chart review was performed at the Advocate Lutheran General Hospital, Christ Medical Center, and Illinois Masonic Medical Center from 2002 to 2012 on patients diagnosed with breast cancer during pregnancy using ICD-9 (International Classification of Diseases - 9th version) codes.

Results Eleven patients between 12 and 37 weeks' gestation matched the search criteria. One patient terminated the pregnancy. Patients in our study were treated appropriately according to guidelines with the following exceptions. Trastuzumab was used in one patient during pregnancy which likely caused the oligohydramnios resulting in an induction of labor at 33 weeks. Three patients were delivered preterm between 34 and 36 weeks without an obstetric indication. Two patients underwent sentinel node biopsy.

Conclusion The diagnosis of breast cancer in pregnancy is an infrequent but devastating diagnosis that is likely to increase. Although sentinel lymph node biopsy is not generally recommended in pregnancy, this may be an outdated guideline as using a low-dose lymphoscintigraphic technique appears to be safe in pregnancy.

Keywords

breast cancer - pregnancy - chemotherapy - sentinel node biopsy

Note

This study was presented at the Annual Meeting of the Central Association of Obstetricians and Gynecologists, October 16–19, 2013, Napa, CA.


 

  • References

  • 1 National Comprehensive Cancer Network. Guidelines breast cancer in pregnancy. Version 3. Available at: www.NCCN.org . Accessed 2013
    PubMedGoogle Scholar
  • 2 Amant F, Deckers S, Van Calsteren K. , et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer 2010; 46 (18) 3158-3168
    CrossrefPubMedGoogle Scholar
  • 3 Loibl S, Han SN, von Minckwitz G. , et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 2012; 13 (09) 887-896
    CrossrefPubMedGoogle Scholar
  • 4 Azim Jr HA, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 2010; 6 (06) 821-826
    CrossrefPubMedGoogle Scholar
  • 5 Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy--case report and literature review. Gynecol Oncol 2001; 80 (03) 405-408
    CrossrefPubMedGoogle Scholar
  • 6 Gropper AB, Calvillo KZ, Dominici L. , et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol 2014; 21 (08) 2506-2511
    CrossrefPubMedGoogle Scholar
  • 7 Spanheimer PM, Graham MM, Sugg SL, Scott-Conner CE, Weigel RJ. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol 2009; 16 (05) 1143-1147
    CrossrefPubMedGoogle Scholar
  • 8 Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med 2006; 47 (07) 1202-1208
    PubMedGoogle Scholar
  • 9 Keleher A, Wendt III R, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J 2004; 10 (06) 492-495
    CrossrefPubMedGoogle Scholar
  • 10 Gentilini O, Cremonesi M, Toesca A. , et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging 2010; 37 (01) 78-83
    CrossrefPubMedGoogle Scholar
  • 11 Rovera F, Chiappa C, Coglitore A. , et al. Management of breast cancer during pregnancy. Int J Surg 2013; 11 (Suppl. 01) S64-S68
    CrossrefPubMedGoogle Scholar
  • 12 Guidroz JA, Scott-Conner CE, Weigel RJ. Management of pregnant women with breast cancer. J Surg Oncol 2011; 103 (04) 337-340
    CrossrefPubMedGoogle Scholar
  • 13 Keleher AJ, Theriault RL, Gwyn KM. , et al. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 2002; 194 (01) 54-64
    CrossrefPubMedGoogle Scholar
  • 14 Theriault RL, Litton JK. Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know?. J Clin Oncol 2013; 31 (20) 2521-2522
    CrossrefPubMedGoogle Scholar
  • 15 Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 2010; 16 (01) 76-82
    PubMedGoogle Scholar